Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.

A Phase 3, Randomized, Double-Blind, Clinical Trial of Pembrolizumab plus Chemotherapy versus Placebo plus Chemotherapy as Neoadjuvant/Adjuvant Treatment for Subjects with Gastric and Gastroesophageal Junction Adenocarcinoma

Clinical Trial Details

This trial is open to women and men age 18 and older with locally advanced resectable gastric or gastroesophageal junction (GEJ) cancer. Cancers of the upper gastrointestinal (GI) tract are a group of highly aggressive malignancies and a problem globally with a 5-year survival rate. In the United States alone, 28,000 new cases of stomach cancer are estimated to be diagnosed in 2017, with approximately 10,960 deaths.

There is no uniformly accepted standard of practice for the management of these patients at this time. There is an urgent need to identify effective new strategies for the treatment of these patients. 

The primary objective of this study is to evaluate the safety and tolerability of pembrolizumab in combination with chemotherapy and overall survival of patients on this treatment. 

Key Eligibility: 
  • Women and men age 18 and older 
  • Diagnosis of untreated localized gastric or gastroesophageal junction (GEJ) cancer 
  • Be willing to provide tissue samples 
  • Detailed eligibility reviewed when you contact the study team

Study contact by location

Upper East Side - Manhattan

Contact(s)

Carina Puello, RN
(646) 962-3541
cap4008@med.cornell.edu

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:

1712018827

ClinicalTrials.gov:

NCT03221426

Sponsor:

MK-3475-585

Status

Open to Enrollment

Age Group

Adult

Sponsor